MTOR and breast carcinoma: Lehmann and colleagues discovered that the IC50 of a PI3K/mTOR inhibitor, NVP–BEZ235, for MDA–MB–231 was lower than that for HCC–1937, and that breast cancers of M and MSL subtypes were more sensitive to PI3K/mTOR inhibitor treatment [23].